EU industry needs more supportive regulator as technologies blur
This article was originally published in Clinica
Executive Summary
The EU medical devices industry has long lamented the legal uncertainties surrounding products on the drug and device borderline. And such borderline products confusion - and frustrations for companies - are set to grow further as new legislation is implemented to take account of emerging technologies, including the forthcoming Human Tissue Engineering Product Regulation, writes Amanda Maxwell.